110 related articles for article (PubMed ID: 16012901)
1. Formulations strategies for biopharmaceuticals--ensuring success to market.
Atkinson EM; Klum W
IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
4. Optimization of pharmaceutical formulations for therapy.
Kofi-Tsekpo MW
Afr J Health Sci; 1994 Feb; 1(1):13-19. PubMed ID: 12150638
[TBL] [Abstract][Full Text] [Related]
5. Defining and characterizing the late-stage biopharmaceutical pipeline.
Nagle PC; Lugo TF; Nicita CA
Am J Manag Care; 2003 Oct; 9(6 Suppl):S124-35. PubMed ID: 14577717
[TBL] [Abstract][Full Text] [Related]
6. Preclinical formulations for discovery and toxicology: physicochemical challenges.
Neervannan S
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
[TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
8. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
9. Extemporaneous drug formulations.
Nahata MC; Allen LV
Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
[TBL] [Abstract][Full Text] [Related]
10. Oral heparin (Emisphere).
Dunn A
IDrugs; 2000 Jul; 3(7):817-24. PubMed ID: 16080057
[TBL] [Abstract][Full Text] [Related]
11. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
12. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Sudhakar Y; Kuotsu K; Bandyopadhyay AK
J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
[TBL] [Abstract][Full Text] [Related]
13. European perspectives on pediatric formulations.
Breitkreutz J
Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
[TBL] [Abstract][Full Text] [Related]
14. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
16. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
17. The role of formulation in insulin comparability assessments.
Defelippis MR; Larimore FS
Biologicals; 2006 Mar; 34(1):49-54. PubMed ID: 16330222
[TBL] [Abstract][Full Text] [Related]
18. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development.
Warne NW
Eur J Pharm Biopharm; 2011 Jun; 78(2):208-12. PubMed ID: 21406226
[TBL] [Abstract][Full Text] [Related]
19. Sub-visible particle quantitation in protein therapeutics.
Cao S; Jiao N; Jiang Y; Mire-Sluis A; Narhi LO
Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):73-9. PubMed ID: 20144454
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on stability of protein drug products during formulation, fill and finish operations.
Rathore N; Rajan RS
Biotechnol Prog; 2008; 24(3):504-14. PubMed ID: 18484778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
